Tyrosine-protein kinase JAK2


  • Accession: Q62120
  • Swissprot: JAK2_MOUSE
  • Organism: Mus musculus
  • Gene: Jak2
  • Target classes: Kinase, Unclassified

Drug Relations:

Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. Bioactivity details MOA